Skip to content

Clinical study on treatment of Qilin Pills with diminished ovarian reserve: a blind, multicenter randomized control study

Clinical study on treatment of Qilin Pills with diminished ovarian reserve: a blind, multicenter randomized control study

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-17012824
Enrollment
Unknown
Registered
2017-09-27
Start date
2017-10-15
Completion date
Unknown
Last updated
2017-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diminished ovarian reserve

Interventions

Experimental group:Qilin pills, 2 times a day, every time6g
Control group:Progesterone pill

Sponsors

First Affiliated Hospital of Guangzhou Traditional Chinese Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 39 Years

Inclusion criteria

Inclusion criteria: 1. Diagnostic criteria that meet the decline of ovarian reserve function; 2. Compliance with TCM diagnostic criteria for the spleen-kidney deficiencyInsufficiency of chong mai blood; 3. Women aged 18 to 39 years old; 4. Voluntary consent to sign informed consent and agree to participate in all visits and inspections and treatment according to the requirements of the research programme; 5. No family planning procreation within 3 months and to confirm the method of birth control accepted by the researcher.

Exclusion criteria

Exclusion criteria: 1. The function of ovarian reserve was reduced to organic disease, ovarian surgery and chemoradiotherapy; 2. A patient with a history of malignant or malignant tumors known or suspected; 3. Hyperprolactin or polycystic ovary syndrome; 4. Unexplained vaginal bleeding incurable; 5. Hormone therapy has been used for nearly three months; 6. The menstrual cycle is more than 10 days early; 7. The menstrual cycle extended over 30 days; 8. Pregnant and lactating women; 9. Allergic to physical or drug allergy; 10. Serious primary diseases such as heart, brain, liver and hematopoietic system were combined; 11. Uncooperative, such as mentally ill; 12. Other clinical trials were being performed or other clinical trials were performed within the first 3 months 13. According to the researchers' judgment, there are other lesions or conditions that reduce the possibility of entering a group or complicating the group.

Design outcomes

Primary

MeasureTime frame
Anti-Müllerian hormone;Antral Follicular Count;Basal Follicle-stimulating hormone;Base estradiol;

Secondary

MeasureTime frame
The Chinese medicine certificate waits curative effect;

Countries

China

Contacts

Public ContactDeng Gaopi

First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine

denggaopi@126.com+86 13005162679

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026